Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A.
Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden - a cross-sectional study.

European Journal of Dermatology. 2012 Mar-Apr;22(2):238-45.

Ghatnekar O, Hjortsberg C, Gisslén M, Lindbäck S & Löthgren M
Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden
Pharmacoeconomics, 2010; 28 Suppl 1: 49-57

Ghatnekar O, Hjalte F &Taylor M
Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib - a Swedish model application
Acta Oncol. 2010 Aug; 49(6): 851-8

Arana A, Allen S, Burkowitz J, Fantoni V, Ghatnekar O, Rico M T, Vanhaverbeke N, Wentworth C E, Brosa M & Arellano F M
Infliximab Paediatric Crohn’s Disease Educational Plan. A European, Cross-Sectional, Multicentre Evaluation
Drug Safety Journal 2010; 33(6): 489-501

Ghatnekar O & Glader, E-L
The effect of atrial fibrillation on stroke-related inpatient costs in Sweden: a 3-year analysis of registry incidence data from 2001
Value in Health, 2008; 11(5):862-868

Ghatnekar O, Alvegård T, Conradi N, Lenhoff S, Mellqvist UH, Persson U &Löthgren M
Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis
Clinical Therapeutics. 2008;30(9):1704-1713